Included in the formulation
АТХ:J.05.A.H.01 Zanamivir
Pharmacodynamics:An antiviral agent. Selectively inhibits neuraminidase, the surface enzyme of the influenza virus. It disrupts the replication of influenza A and B viruses, neutralizes all known subtypes of influenza A neuraminidase. Inhibits the release of viruses from the epithelial cells of the respiratory tract.
Pharmacokinetics:Means for topical application. With inhalation, absorption is low, systemic effects on the body do not.
Indications:It is used for treatment and prevention of influenza A and B.
X.J10-J18.J10 Influenza caused by an identified influenza virus
Contraindications:Age up to 5 years, individual intolerance.
Carefully:Pregnancy and lactation, hypersensitivity.
Pregnancy and lactation:Recommendations for FDA - Category B. Applicable with caution, in cases where the expected effect exceeds the risk to the fetus and newborn.
Dosing and Administration:Inhalation of 5 mg, the first day after 2 hours, then after 12 hours at the same time. The course of treatment is 5 days. Possible use with a preventive goal up to 1 month.
The highest daily dose: 60 mg.
The highest single dose: 5 mg.
Side effects:Central and peripheral nervous system: headache, fatigue.
Respiratory system: rhinitis, rarely - bronchospasm.
Musculoskeletal system: myalgia, arthralgia.
Dermatological reactions: hives.
Allergic reactions.
Overdose:Cases of overdose are not described.
Treatment is symptomatic.
Interaction:Inhalation bronchodilators are used before inhalation of zanamivir.
Special instructions:It is recommended for use in the first two days of clinical manifestations of influenza.